These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 16826363)

  • 1. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rational approach to evidence gaps in the management of osteoporosis.
    Rosen CJ; Brown SA
    Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study.
    Nielsen DS; Langdahl BL; Sørensen OH; Sørensen HA; Brixen KT
    Scand J Public Health; 2010 Jul; 38(5):502-7. PubMed ID: 20484306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis: latest innovation in therapy.
    Taechakraichana N; Witoonpanich P
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S126-31. PubMed ID: 21213509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment options for osteoporosis.
    Adachi JD
    J Rheumatol Suppl; 1996 Aug; 45():11-4. PubMed ID: 8856645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognosis for dental implants placed in patients taking oral bisphosphonates.
    Kasai T; Pogrel MA; Hossaini M
    J Calif Dent Assoc; 2009 Jan; 37(1):39-42. PubMed ID: 19263627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates in the treatment of osteoporosis.
    Dreyfuss BJ; Rai DS
    West J Med; 1997 Sep; 167(3):177-8. PubMed ID: 9308413
    [No Abstract]   [Full Text] [Related]  

  • 16. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
    MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
    Greenspan SL; Harris ST; Bone H; Miller PD; Orwoll ES; Watts NB; Rosen CJ
    Am Fam Physician; 2000 May; 61(9):2731-6. PubMed ID: 10821153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral health status of patients on oral bisphosphonates for osteoporosis.
    Kunchur R; Goss AN
    Aust Dent J; 2008 Dec; 53(4):354-7; quiz 366. PubMed ID: 19133952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.